Vectura Group continues to seek partner for VR647 Phase III development
The company said, "Vectura made a positive start to trading in 2019, with flutiform in-market demand and partner supply chain management resulting in product supply revenues being ahead of the Board's expectations for H1 2019. Given the Group's visibility of flutiformproduct supply volumes for the rest of 2019, the Group expects this strong performance to continue into the second half of the year. Following a constructive end of Phase II meeting with the FDA in May, Vectura continues to seek a partner for VR647 Phase III development and commercialisation. Irrespective of the outcome of these discussions the Group maintains its financial guidance and outlook expectations for 2019. Vectura will report its interim results for the six-months ended 30 June 2019 on Tuesday 10 September 2019."